Asian Spectator


The Times

.

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

  • Written by PR Newswire Asia - Asian Spectator
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
  • IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.
  • Maximum dose reached with no dose-limiting toxicities observed.
  • TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma.

MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 /PRNewswire/ --...

Magazine

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

hacklink hack forum hacklink film izle hacklink z-libraryesim senegalbetparkbetparktelegram下载zlibrary bookscasino en ligneWPS下载IND RUMMYnon gamstop casinosnon gamstop casinos uknon gamstop casinoscasinos not on gamstopcasinos not on gamstopnon gamstop casinoonline gamblinguk casinosuk casinosStreamEastStreamEastjojobetmeritkingcashnow.imweb.mecasibomcasibomjojobetnakitbahismatbetmatbet girişjojobet